Skip to content
Assyro AI
Purple Book reference family · 351(a) biologic

tagraxofusp-erzs (Elzonris)

tagraxofusp-erzs is an FDA-licensed reference biologic from Stemline Therapeutics, Inc..

351(a) biologicBLA 761116 Stemline Therapeutics, Inc.
Biosimilars
0
Interchangeables
0
Listed patents
0
Reference approved
2018

Reference product

Originator biologic
Ask AI
351(a)BLA 761116

Elzonris tagraxofusp-erzs

Stemline Therapeutics, Inc.

View full reference-product record
Approved
Marketing
Rx
Center
CDER
Patents
None listed

Exclusivity & patent cliffs

Protection horizon
Ask AI
  1. Reference approval

    Approval date of the reference tagraxofusp-erzs product.

    8 yr ago

  2. Orphan exclusivity ends

    7-year orphan-drug exclusivity window.

    11 mo ago

tagraxofusp-erzs: frequently asked questions

Reference exclusivity, biosimilars, interchangeability, and patents for this molecule, from the FDA Purple Book.

Built from official FDA Purple Book records (monthly downloads, the Advanced Search interface, and the published Patent List), with reference-product, license-type, and exclusivity context for tagraxofusp-erzs.

Related FDA reference tools

Assyro Intelligence

Ask anything about tagraxofusp-erzs

Cited answers from FDA, EMA, Health Canada, PubMed and ClinicalTrials.gov, in seconds. Free, no sign-up.

  • PubMed
  • ClinicalTrials.gov
  • FDA
  • Health Canada
  • EMA
  • ICH

Evaluating for a team? Book a demo